Literature DB >> 21374800

Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells.

John D Clarke1, Anna Hsu, Zhen Yu, Roderick H Dashwood, Emily Ho.   

Abstract

SCOPE: Sulforaphane (SFN) is an isothiocyanate derived from cruciferous vegetables such as broccoli. The ability of SFN to inhibit histone deacetylase (HDAC) enzymes may be one mechanism by which it acts as a chemoprevention agent. The ability of a chemopreventive agent to specifically cause cytotoxicity in cancer and not normal cells is an important factor in determining its safety and clinical relevance. METHODS AND
RESULTS: We characterized the effects of SFN in normal (PrEC), benign hyperplasia (BPH1) and cancerous (LnCap and PC3) prostate epithelial cells. We observed that 15 μM SFN selectively induced cell cycle arrest and apoptosis in BPH1, LnCap and PC3 cells but not PrEC cells. SFN treatment also selectively decreased HDAC activity, and Class I and II HDAC proteins, increased acetylated histone H3 at the promoter for P21, induced p21 expression and increased tubulin acetylation in prostate cancer cells. HDAC6 over-expression was able to reverse SFN-induced cyotoxicity. In PrEC cells, SFN caused only a transient reduction in HDAC activity with no change in any other endpoints tested. The differences in sensitivity to SFN in PrEC and PC3 are likely not due to differences in SFN metabolism or differences in phase 2 enzyme induction.
CONCLUSION: SFN exerts differential effects on cell proliferation, HDAC activity and downstream targets in normal and cancer cells.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21374800      PMCID: PMC3129466          DOI: 10.1002/mnfr.201000547

Source DB:  PubMed          Journal:  Mol Nutr Food Res        ISSN: 1613-4125            Impact factor:   5.914


  38 in total

Review 1.  Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell.

Authors:  Ø Bruserud; C Stapnes; E Ersvaer; B T Gjertsen; A Ryningen
Journal:  Curr Pharm Biotechnol       Date:  2007-12       Impact factor: 2.837

Review 2.  HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention.

Authors:  X-J Yang; E Seto
Journal:  Oncogene       Date:  2007-08-13       Impact factor: 9.867

Review 3.  Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis.

Authors:  Jane V Higdon; Barbara Delage; David E Williams; Roderick H Dashwood
Journal:  Pharmacol Res       Date:  2007-01-25       Impact factor: 7.658

4.  Histone deacetylase inhibitors selectively suppress expression of HDAC7.

Authors:  Milos Dokmanovic; Gisela Perez; Weisheng Xu; Lang Ngo; Cathy Clarke; Raphael B Parmigiani; Paul A Marks
Journal:  Mol Cancer Ther       Date:  2007-09       Impact factor: 6.261

5.  Expression profile of class I histone deacetylases in human cancer tissues.

Authors:  Masamune Nakagawa; Yoshinao Oda; Takashi Eguchi; Shin-Ichi Aishima; Takashi Yao; Fumihito Hosoi; Yuji Basaki; Mayumi Ono; Michihiko Kuwano; Masao Tanaka; Masazumi Tsuneyoshi
Journal:  Oncol Rep       Date:  2007-10       Impact factor: 3.906

6.  Induction of p21 protein protects against sulforaphane-induced mitotic arrest in LNCaP human prostate cancer cell line.

Authors:  Anna Herman-Antosiewicz; Hui Xiao; Karen L Lew; Shivendra V Singh
Journal:  Mol Cancer Ther       Date:  2007-05       Impact factor: 6.261

Review 7.  Histone deacetylase inhibitors: molecular mechanisms of action.

Authors:  W S Xu; R B Parmigiani; P A Marks
Journal:  Oncogene       Date:  2007-08-13       Impact factor: 9.867

Review 8.  HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination.

Authors:  C Boyault; K Sadoul; M Pabion; S Khochbin
Journal:  Oncogene       Date:  2007-08-13       Impact factor: 9.867

9.  HDAC3 overexpression and colon cancer cell proliferation and differentiation.

Authors:  Colleen C Spurling; Cassandra A Godman; Emily J Noonan; Theodore P Rasmussen; Daniel W Rosenberg; Charles Giardina
Journal:  Mol Carcinog       Date:  2008-02       Impact factor: 4.784

10.  Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy.

Authors:  W Weichert; A Röske; V Gekeler; T Beckers; C Stephan; K Jung; F R Fritzsche; S Niesporek; C Denkert; M Dietel; G Kristiansen
Journal:  Br J Cancer       Date:  2008-01-22       Impact factor: 7.640

View more
  80 in total

Review 1.  Dietary Sulforaphane in Cancer Chemoprevention: The Role of Epigenetic Regulation and HDAC Inhibition.

Authors:  Stephanie M Tortorella; Simon G Royce; Paul V Licciardi; Tom C Karagiannis
Journal:  Antioxid Redox Signal       Date:  2014-12-19       Impact factor: 8.401

Review 2.  Mechanisms of action of isothiocyanates in cancer chemoprevention: an update.

Authors:  Sandi L Navarro; Fei Li; Johanna W Lampe
Journal:  Food Funct       Date:  2011-09-21       Impact factor: 5.396

Review 3.  Targeting the epigenome with bioactive food components for cancer prevention.

Authors:  Thomas Prates Ong; Fernando Salvador Moreno; Sharon Ann Ross
Journal:  J Nutrigenet Nutrigenomics       Date:  2012-02-22

4.  High-performance liquid chromatography-based method to evaluate kinetics of glucosinolate hydrolysis by Sinapis alba myrosinase.

Authors:  Kayla J Vastenhout; Ruthellen H Tornberg; Amanda L Johnson; Michael W Amolins; Jared R Mays
Journal:  Anal Biochem       Date:  2014-07-25       Impact factor: 3.365

5.  The role of Sulforaphane in cancer chemoprevention and health benefits: a mini-review.

Authors:  Reza Bayat Mokhtari; Narges Baluch; Tina S Homayouni; Evgeniya Morgatskaya; Sushil Kumar; Parandis Kazemi; Herman Yeger
Journal:  J Cell Commun Signal       Date:  2017-07-23       Impact factor: 5.782

6.  Epigenetic Regulation by Sulforaphane: Opportunities for Breast and Prostate Cancer Chemoprevention.

Authors:  Lauren L Atwell; Laura M Beaver; Jackilen Shannon; David E Williams; Roderick H Dashwood; Emily Ho
Journal:  Curr Pharmacol Rep       Date:  2015-04-01

Review 7.  Molecular mechanisms of pharmacological doses of ascorbate on cancer cells.

Authors:  Sascha Venturelli; Tobias W Sinnberg; Heike Niessner; Christian Busch
Journal:  Wien Med Wochenschr       Date:  2015-06-12

8.  Sulforaphane induction of p21(Cip1) cyclin-dependent kinase inhibitor expression requires p53 and Sp1 transcription factors and is p53-dependent.

Authors:  Yap Ching Chew; Gautam Adhikary; Gerald M Wilson; Wen Xu; Richard L Eckert
Journal:  J Biol Chem       Date:  2012-03-15       Impact factor: 5.157

9.  3,3'-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells.

Authors:  Laura M Beaver; Tian-Wei Yu; Elizabeth I Sokolowski; David E Williams; Roderick H Dashwood; Emily Ho
Journal:  Toxicol Appl Pharmacol       Date:  2012-07-16       Impact factor: 4.219

Review 10.  Dietary factors and epigenetic regulation for prostate cancer prevention.

Authors:  Emily Ho; Laura M Beaver; David E Williams; Roderick H Dashwood
Journal:  Adv Nutr       Date:  2011-11-03       Impact factor: 8.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.